Jefferies downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $70, after Stryker (SYK) announced an agreement to acquire Inari for $80 per share in cash. Given no product overlap, the firm sees little antitrust risk and expects the deal to close by end of Q1, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Morning Movers: Getty Images, Shutterstock surge following merger pact
- Inari Medical downgraded to Equal Weight from Overweight at Wells Fargo
- BofA goes to No Rating on Inari Medical after takeover deal
- Inari Medical downgraded to Market Perform from Outperform at William Blair
- Inari Medical price target raised at Piper after agreeing to be acquired
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue